Table 2:
Cox regression analyses of urinary lithium excretion with graft failure and kidney function decline in 642 KTRs.
| Graft failure | Kidney function decline | |||
|---|---|---|---|---|
| Model | HR (95% CI) per log2 μmol/24 h | P-value | HR (95% CI) per log2 μmol/24 h | P-value |
| Model 1 | 0.54 (0.38–0.79) | .002 | 0.73 (0.54–0.99) | .041 |
| Model 2 | 0.55 (0.38–0.79) | .002 | 0.72 (0.53–0.97) | .028 |
| Model 3 | 0.59 (0.41–0.86) | .006 | 0.73 (0.54–0.98) | .031 |
| Model 4 | 0.59 (0.41–0.85) | .005 | 0.71 (0.53–0.95) | .021 |
| Model 5 | 0.62 (0.42–0.91) | .016 | 0.73 (0.54–1.00) | .054 |
| Events, n (%) | 79 (12) | 102 (16) | ||
Graft failure was defined as start of dialysis or retransplantation and kidney function decline was defined as a doubling of serum creatinine.
Urinary lithium excretion was log2 transformed prior to analyses.
Model 1: crude. Model 2: adjusted for age and sex. Model 3: model 2, additionally adjusted for BSA, eGFR (Chronic Kidney Disease Epidemiology Collaboration equation based on both serum creatine and cystatin C) and urinary protein excretion. Model 4: model 3, additionally adjusted for smoking status and alcohol intake. Model 5: model 3, additionally adjusted for time between transplantation and baseline, the number of transplantations up to baseline, HLA antibodies, pre-emptive transplantation, deceased donor, donor age, history of rejection, warm ischaemia time, calcineurin inhibitors and proliferation inhibitors.